AMG 110

Drug Profile

AMG 110

Alternative Names: AMG-110; Anti-CD3 anti-EpCAM bispecific antibody - Amgen; MT110; MT110 monoclonal antibody; Solitumomab

Latest Information Update: 24 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD3 antigen inhibitors; Epithelial cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Jan 2015 Amgen completes a phase I trial of AMG 110 in Solid tumours in Germany (NCT00635596)
  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 08 Jun 2010 Interim efficacy & adverse events data from a phase I trial of IV MT 110 in Solid tumours (lung, gastrointestinal) presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top